Last reviewed · How we verify
NCT06077383
Effect of Weizmania Coagulans BC99 Intervention on Gut Microbiota and Metabolic Markers in Overweight/Obese Adults
NA trial testing Weizmania Coagulans BC99 in Overweight in 72 participants. Completed in 30 July 2024.
30 July 2024
Quick facts
| Lead sponsor | Qilu Hospital of Shandong University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 72 |
| Start date | 25 October 2023 |
| Primary completion | 30 July 2024 |
| Estimated completion | 30 July 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Weizmania Coagulans BC99
Conditions studied
- Overweight — all drugs for Overweight →
Sponsor
Qilu Hospital of Shandong University
Who can join
Adults 18 to 65, any sex, with Overweight. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main purpose of this study is to verify the effects of Weizmania Coagulans BC99 on the gut microbiota and fat related markers (TG, TC, HDL, LDL) in overweight/Obese adult subjects. The subjects participate were randomly grouped and receive intervention with Weizmann clotting bacteria BC99 or placebo. The total duration of the study is 8 weeks. After the intervention, blood, urine, and feces samples of the subjects need to be collected and promptly tested in the laboratory. During the intervention period, each group of subjects was required to take the corresponding product daily and record complications.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Effect of <i>Bacillus coagulans</i> BC99 supplementation on body weight and gut microbiota in overweight and obese individual: a randomized, double-blind, placebo-controlled study.
Wang R, Zhang G, Wang X, Xing Z, et al · · 2025 · PMID 40416368 · DOI 10.3389/fnut.2025.1542145
Verify or expand the search:
- PubMed search for NCT06077383
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Overweight
Currently open trials in the same condition.
- NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
- NCT07472881 — Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women · NA · recruiting
- NCT07465965 — A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults · Phase 1 · recruiting
- NCT07407348 — A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the · Phase 1 · recruiting
- NCT07400653 — A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) · Phase 3 · recruiting
Other Qilu Hospital of Shandong University trials
Trials by the same sponsor.
- NCT06704074 — Virtual Reality Task Oriented Training on Upper Limb Function in Stroke Patients · NA · recruiting
- NCT07140419 — Coronary Computed Tomographic Angiography Combined With CT-FFR in Intermediate-Risk Chest Pain Patients. · NA · not yet recruiting
- NCT07509879 — Research on the Molecular Mechanism of Cognitive Differences Between Williams Syndrome and Autism Spectrum Disorder · not yet recruiting
- NCT07537374 — A Case-Control Observational Study of Peripheral Blood-Derived iPSC Models to Investigate Oligodendrocyte Lineage Develo · not yet recruiting
- NCT07505940 — Bilateral Comparison of Unilateral Sacral Neuromodulation Test Stimulation in the Treatment of Neurogenic Bladder · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06077383 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Qilu Hospital of Shandong University
- Last refreshed: 6 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06077383.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing